Data-Gouv-ML/pcri-informations-sur-les-projets-laureats huggingface dataset:
Invasive cognitive brain computer interfaces to enhance and restore attention: proof of concept and underlying cortical mechanisms. (Brain3.0)

Framework: Horizon 2020 — Excellent Science
Programme: European Research Council (ERC)
Theme: European research council
Destination: Consolidator grants
Action type: ERC actions
Panel: Neuroscience and Disorders of the Nervous System
Panel description: Nervous system development, homeostasis and ageing, nervous system function and dysfunction, systems neuroscience and modelling, biological basis of cognitive processes and of behaviour, neurological and mental disorders
Countries involved: France
Call: ERC Consolidator Grant (ERC-2015-CoG, 2015)
Start date: 2016-10-01
End date: 2023-09-30
Duration (months): 84.0
Total project cost (EUR): 1997748.0
EU funding (EUR): 1997748.0
Participants: 1
Project status: SIGNED

The present project focuses on a barely scratched aspect of invasive cognitive brain-computer interfaces (cBCIs), i.e. closed-loop invasive cBCIs to augment and restore attentional functions. Its aim is to achieve an efficient enhanced cognition protocol both in the healthy brain and in the damaged brain and to study the local and global plasticity mechanisms underlying these effects. The project relies on the unique methodological combination of multi-electrode multisite intracortical recordings and functional magnetic resonance imaging, in association with reversible cortical lesions and intracortical microstimulations, in an experimental model allowing to approach the attentional human function and its dysfunctions to the best. Our goal is to achieve: 1. A closed-loop invasive cBCI for augmented attention, by providing the subjects with a feedback on their cortical spatial and feature attention information content as estimated from real-time population decoding procedures, using reinforcement learning, to have them improve this cognitive content, and as a result, improve their overt attentional behavioural performance. 2. A closed-loop invasive cBCI for restored attention, by inducing a controlled attentional loss thanks to reversible cortical lesions targeted to key functionally-identified cortical regions and using the closed-loop cBCI to restore attentional performance. 3. An invasive cBCI for stimulated attentional functions. We will identify the neuronal population changes leading to a voluntary enhancement of attentional functions as quantified in aim 1 and inject these changes, using complex patterns of microstimulations, mimicking spikes, to enhance or restore attention, in the absence of any active control by the subjects. This project will contribute to the development of novel therapeutical applications to restore acute or chronic severe attentional deficits and to provide an in depth understanding of the neural bases underlying closed-loop cBCIs.

Keywords: non human primate,neurofeedback,multi electrode recordings,enhancing cognition,resotring cognition,plasticity
OWise for Europe - A feasibility study of a pan-European mobile app providing people with cancer with useful tools and treatment information in one easily accessible place. (OWISE4EU)

Framework: Horizon 2020 — Societal Challenges
Programme: Health, demographic change and wellbeing
Theme: Active ageing and self-management of health
Action type: SME instrument
Countries involved: Netherlands
Call: Accelerating market introduction of ICT solutions for Health, Well-Being and Ageing Well (H2020-SMEINST-1-2016-2017, 2016)
Start date: 2016-03-01
End date: 2016-08-31
Duration (months): 6.0
Total project cost (EUR): 71429.0
EU funding (EUR): 50000.0
Participants: 1
Project status: CLOSED

Cancer is a big issue worldwide with 70% increase in incidence in the next 20 years. Around 3 million people are diagnosed with cancer in Europe annually and it costs the EU more than €126 bn/yr. To improve clinical outcomes of treatments, to reduce side-effects and to increase patients’ quality of life we need to accurately understand how patients experience cancer treatments. Px HealthCare (also called Px, which stands for Patient Experience) has developed OWise, an independently validated, mobile medical platform supporting cancer patients during treatment. OWise is a real game-changer as - its award-winning app was shown to improve both patient experience and the patient-doctor interaction - while the fully anonymised Patient Reported Outcome data (PRO) are collected and investigated using advanced data-analytics to improve oncology outcomes. As OWise is prescribed by physicians, it is the first oncology platform connecting patients, physicians and payers with the clear potential to benefit all 3 groups. OWise is a novel way for patients to be actively engaged in their treatment and receive customised medical support. It is also a new way for clinicians to receive PRO data and to adjust treatment in between hospital visits. Px’ revenue model is based on licensing insights it generates from the PRO data to health care insurers and pharmaceutical companies who have expressed their great need for it. Initially launched for breast cancer in the Netherlands and the UK, Px is now developing OWise for all cancer types and plans to employ it swiftly across Europe, preferably with the aid of all 3 Phases of the present programme. Aim of Phase 1 project is to develop of a business plan to roll-out OWise in EU countries, reaching at least 1 million EU cancer patients annually in 2020, providing >20% of these with access to OWise while improving cancer outcomes through its PRO data analysis. Px’ revenues are expected to go up by 30% by 2020, due to this programme.

Keywords: mobile app,cancer,patient empowerment,patient reported outcomes,guideline based care,big data
The world's first universally compatible algorithm and platform for automatic interpretation of electrocardiogram analysis data (SmartECG)

Framework: Horizon 2020 — Societal Challenges
Programme: Health, demographic change and wellbeing
Theme: Active ageing and self-management of health
Action type: SME instrument
Countries involved: Finland
Call: Accelerating market introduction of ICT solutions for Health, Well-Being and Ageing Well (H2020-SMEINST-2-2016-2017, 2016)
Start date: 2017-03-01
End date: 2019-05-31
Duration (months): 27.0
Total project cost (EUR): 1750787.5
EU funding (EUR): 1225551.25
Participants: 1
Project status: CLOSED

RemoteA, experienced telemedicine services developer and provider from Finland, has created a unique SmartECG tool for primary care phychians that includes a smart algorithm based electocardiogram (ECG) analysis software which enables automatic interpretation of ECG analysis data from any monitoring device and a simple international telemedicine service platform for requesting fast consulations from cardiologists. The innovation helps to address the severe cardiovasucalr diseases (CVD) challenge - the most critical and expensive healthcare problem in EU with more than 2 million casualties and €200 billion cost each year. However – since 80% of premature heart diseases are preventable, the CVD treatment field has experienced significant innovation and improvement over the last decade, especially in terms of longer analysis by remote monitoring. But the ongoing shift towards personalised healthcare, remote monitoring and telemedicine solutions are creating huge streams of analysis data that need to be interpreted by primary and secondary care professionals. This has put the whole healthcare system under heavy pressure and impeded actual implementation of medical innovations and best treatment practices. The SmartECG simple, yet very effective solution will significantly improve the CVD treatment even with current healthcare resources and equipment. The universally compatible software makes the exising ECG devices smarter and empowering the primary care physchians to perform more ECG analysis and enables wider range of people to be analysed faster, more thoroughly and more frequently than with current solutions. As a result of the SME-project, we have finalised our SmartECG solution, ensured market clearance in all targeted regions and are ready to start full scale market introduction in Q1/2019. By 2020, our SmartECG platform will be used by more than 10 000 GPs and specialist physicians, serving approximately 800 000 patients annually.

Keywords: clinical decision support tools,medical algorithms,telemedicine
Manipulating and tuning dynamic characteristics of soft electro-active materials: Modelling, simulations and experiments (DYN-SEAM)

Framework: Horizon 2020 — Excellent Science
Programme: Marie-Sklodowska-Curie Actions
Theme: Marie Skłodowska-Curie
Destination: Individual Fellowships (IF)-Standard European Fellowships
Action type: Marie Skłodowska-Curie actions
Panel: Information Science and Engineering
Countries involved: Ireland
Call: Individual Fellowships (H2020-MSCA-IF-2019, 2019)
Start date: 2020-08-01
End date: 2022-07-31
Duration (months): 24.0
Total project cost (EUR): 196590.72
EU funding (EUR): 196590.72
Participants: 1
Project status: CLOSED

Dr. Bin Wu is a Chinese national, trained in Applied Mechanics and Multi-physics in China, Germany, and Italy. He is applying for a two-year MSCA Fellowship to conduct the DYN-SEAM action at NUI Galway, Ireland. Due to striking advantages such as rapid response and large deformation under electric stimuli, and significant changes of dynamic characteristics induced by biasing fields (pre-stretch, electric stimuli, etc.), soft electro-active materials (SEAMs) have found multiple and practical applications in the real world, including actuators, energy harvesters, biomedical devices, flexible electronics, tunable resonators, and wave devices. However, a systematic understanding of their dynamic behaviours is still lacking, creating a bottleneck to innovation. The action aims at conducting an in-depth investigation of the effects of key factors (inhomogeneity, anisotropy, viscoelasticity, fluid-solid interaction, periodic structures) on the dynamic characteristics of SEAMs under biasing fields, with special attention in exploring promising applications, such as ultrasonic non-destructive testing and ultrasound elastography, smart design of self-sensing actuators, tunable resonators, and soft intelligent wave devices. The action mixes ad-hoc theoretical modelling with experimental tests and numerical simulations, by taking full advantage of the host and partner institutions' expertise and facilities, and experience in scientific management, intellectual property, etc. Secondments include a period at an acoustics laboratory (academic) and another at an enhanced hearing company (non-academic). This international, inter-sectoral and inter-disciplinary action will enable novel technological advances in material/life science and engineering—contributing to Europe 2020 'Innovation Union' initiative and European excellence. It will allow the researcher to grow as a world-class leader for these emerging fields, with a unique blend of expertise and hands-on experience.

Keywords: soft electro active material,dynamic behaviour,experimental test,finite element simulation,self sensing actuator,tuneable resonator,soft intelligent wave device,ultrasound elastography
A Novel Smart System for the safe Management of Nautical operations (SafePort)

Framework: Horizon 2020 — Industrial Leadership
Programme: Innovation in SMEs
Action type: SME instrument
Countries involved: Spain
Call: SME instrument (H2020-SMEInst-2018-2020-1, 2019)
Start date: 2019-12-01
End date: 2020-04-30
Duration (months): 5.0
Total project cost (EUR): 71429.0
EU funding (EUR): 50000.0
Participants: 1
Project status: CLOSED

Shipping is the lifeblood of the global economy, transporting approximately 90% of global trade. However, as the port traffic increases, the interaction between ships and port infrastructure (navigation channels, manoeuvring areas, docks, rivers, locks, etc.) gets more complicated, resulting in system saturation, and hence a greater likelihood of marine accidents occurring. There are very powerful meteorological forecast tools, which provide very valuable information for marine traffic management but they are incomplete and have not even been applied in the clear majority of ports. In this context, Siport21 has developed SafePort, a technology for providing port managers with the most complete and reliable decision tools to manage the operations of the vessels. This technology collects real-time information about the ship approaching the port, as well as meteorological and maritime data, determines whether the operation is viable or not and the requirements to perform the operation in the safest manner. The global marine port and service is a huge market (€ 68.5 bn in 2018) that keeps on growing at a frantic pace, hoping to reach € 78.4 bn by 2023 and hence growing at a Projected CAGR of 4.2%. In this context, SafePort will play an essential role based on its potential to manage nautical operations. We will target the port authorities and terminal operators of the maritime sector. Following our business strategy, SafePort will be sell as a core product considering considered a selling price of 50,000 euros per port. We will also offer specific consulting (upfront revenue) and software updates (annual fee) services, whose prices will be based on the port complexity. Based on this price policy, our nautical operations management technology will provide a revenue of € 15.6 M by the third year, meaning a cumulative cash flow of € 9.9M. Considering a total investment of € 2.2M, we expect to get a ROI of 350% in 3 years.

Keywords: safe nautical operations,automation and control systems,critical infrastructure,emergency systems,security,safety engineering,navigation,guidance,control and tracking,risk management
Star formation quenching and feedback in galaxies throughout the cosmic epochs (QUENCH)

Framework: Horizon 2020 — Excellent Science
Programme: European Research Council (ERC)
Theme: European research council
Destination: Advanced grants
Action type: ERC actions
Panel: Universe sciences
Panel description: Astro-physics/-chemistry/-biology; solar system; planetary systems; stellar, galactic and extragalactic astronomy; cosmology; space sciences; astronomical instrumentation and data
Countries involved: United Kingdom
Call: ERC Advanced Grant (ERC-2015-AdG, 2015)
Start date: 2016-10-01
End date: 2023-03-31
Duration (months): 78.0
Total project cost (EUR): 2484531.0
EU funding (EUR): 2484531.0
Participants: 1
Project status: SIGNED

Throughout the whole life of the universe only 4% of the baryons have been converted into stars, implying that some physical processes must be responsible for suppressing star formation in galaxies. Within this context, one of the most hotly debated open questions is the identification of the process responsible for quenching star formation in galaxies and transforming them into passive and quiescent (gas poor) systems. Theories of galaxy formation have proposed various possible mechanisms, such as: gas removal by powerful outflows or ram pressure stripping, heating and photoionization of the interstellar medium, turbulent or gravitational quenching, halting of the gas supply inflow (often referred to as "strangulation"). The relevance and relative role of these mechanisms (as a function of cosmic epoch, galaxy properties and environment), especially at high redshift, are not yet understood because the constraints provided by current observational data have not yet been able to discriminate between different scenarios. In the proposed project I will make use of some of the most advanced observational facilities that will be available in the coming years to tackle this major outstanding open issue. More specifically, I will exploit the James Webb Space Telescope, MOONS (the next generation multi-object spectrograph at the ESO-VLT) and the Atacama Large Millimeter Array (ALMA). Observing programs making use of these unique facilities will provide an unprecedented amount of information, with unprecedented quality, that will enable us to discriminate between various quenching and feedback processes proposed by theories. More specifically, the aim of this project is to identify and quantify the dominant quenching and feedback mechanisms in galaxies as a function of redshift, as a function of galaxy properties and as a function of environment. The groundbreaking results of this project will be a benchmark for any model of galaxy evolution.

Keywords: galaxy outflows,metallicity evolution,galaxy enviroment
Genetic analysis of rare and common variation in a large Brazilian bipolar family (BBFGEN)

Framework: Horizon 2020 — Excellent Science
Programme: Marie-Sklodowska-Curie Actions
Theme: Marie Skłodowska-Curie
Destination: Individual Fellowships (IF)-Standard European Fellowships
Action type: Marie Skłodowska-Curie actions
Panel: Life Sciences
Countries involved: United Kingdom
Call: Marie Skłodowska-Curie Individual Fellowships (IF-EF) (H2020-MSCA-IF-2014, 2014)
Start date: 2015-05-01
End date: 2017-04-30
Duration (months): 24.0
Total project cost (EUR): 183454.8
EU funding (EUR): 183454.8
Participants: 1
Project status: CLOSED

This proposal describes my aim to use a uniquely large multigenerational family to better understand the genetic underpinnings of mood disorders: the Brazilian Bipolar Family (BBF). The family has a high incidence of mood disorders, featuring diminishing age of onset over generations and assortative mating, whereby many of the marriages in the family are between individuals with a psychiatric disorder. Mood disorders are leading contributors to the global burden of disease. Bipolar disorder is characterized by periods of elevated mood and periods of depression. Major depressive disorder is characterized by pervasive and persistent low mood, low self-esteem and loss of interest or pleasure in normally enjoyable activities. Heritability estimates are 37% for MDD and up to 75% for BP. The current picture for complex disorders is of a genetic architecture consisting of both common and rare variants contributing risk. Genetic studies of mood disorders have not yet individual variants/genes accounting for a large increase in risk. The effect of common variants in the family context is unclear. I propose to utilize the BBF as a unique resource for studying both common and rare variation in mood disorders. Its size offers a powerful means for mapping genetic loci for mood disorders that are individually rare but common within the family. It also provides us with a unique model in which to analyse individual genetic risk profiles, utilizing the large sample size of and predictive ability of previous case-control association studies for each family member into a polygenic risk score. This will also allow me to assess assortative mating, which may act to increase polygenic risk to mood disorders over generations. I will develop an approach which will allow me to incorporate genome-wide case-control study results into family studies – something with broad utility for the field. My study will shed light on the genetic pathology of mood disorders, aiding prevention and treatment.

Keywords: bipolar disorder,major depressive disorder,mood disorders,family study,pedigree,polygenic risk score,rare variation,copy number variation,linkage analysis,assortative mating,anticipation
IDENTIfication and tracking of cancer-prone cells in KIdney Tubules (IDENTIKIT)

Framework: Horizon Europe — Excellent Science
Programme: European Research Council (ERC)
Theme: European research council
Destination: Starting grants
Action type: ERC actions
Panel: Physiology in Health, Disease and Ageing
Panel description: Organ and tissue physiology, comparative physiology, physiology  of ageing , pathophysiology, inter - organ and tissue communication, endocrinology, nutrition,  metabolism, interaction with the microbiome, non -communicable diseases including cancer (and except disorders of the nervous system  and immunity -related diseases)
Countries involved: Italy
Call: ERC STARTING GRANTS (ERC-2024-STG, 2024)
Start date: 2025-01-01
End date: 2029-12-31
Duration (months): 60.0
Total project cost (EUR): 1500000.0
EU funding (EUR): 1500000.0
Participants: 2
Project status: SIGNED

Understanding what makes our cells prone to develop cancer is key for identifying effective strategies of tumor prevention. By analyzing the genome of normal human cells, I obtained compelling evidence that the pattern of somatic mutations can be used to identify the cell-of-origin of kidney cancer. Although every cell accumulates somatic mutations during a lifetime, some are exposed to a specific mutational process that leave a detectable mark in their genome. Kidney cancers and their cell-of-origin show the same genetic mark, consisting of excess somatic point mutations with unique characteristics and unknown origin. We plan to use this mutational signature to track cancer-prone cells in human kidneys and a) follow their population dynamics; b) study their genome and transcriptome at a single cell level; c) understand the underlying causes of excessive mutation. Having already established a non-invasive assay to detect cancer-prone cells in urine samples, we can now analyse numerous donors, longitudinally and without biopsies. Our preliminary analyses point to adaptation to low-oxygen conditions (hypoxia) as the likely cause of excessive mutation in kidney cells and suggest defects in specific DNA repair pathways as a mechanism. We will test whether overactivation of hypoxia signalling, caused by either a genetic syndrome or exposure to renal ischemia, induces the kidney-specific mutational signature in humans. We will then dissect the molecular mechanism by functional experiments in vitro and in mouse models. Finally, we will test whether and how the diet contributes to the expansion of the mutation-prone cell subset in mouse kidneys. Overall, this study will provide unprecedented resolution of early events leading to kidney cancer initiation and will determine whether hypoxic stress is mutagenic and cancer-promoting. Further, this project will pursue the novel idea that cells can be tracked and possibly arrested before cancer initiation.

Keywords: kidney,dna repair,metabolism,nutrition,genetic diseases,hypoxia,vhl,oncometabolites,